Completed
OBSERVATIONAL
NCT04469855
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With OzempicĀ®
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to assess the safety of long-term treatment with OzempicĀ® in patients with type 2 diabetes mellitus. People will get OzempicĀ® as prescribed by their doctor. People will be in this study about 3 years. People above the age of 18 will be asked to fill in the quality of life (QOL) questionnaire (the QOL questionnaire is for the assessment of the influence of diabetes treatment on people's life). There is a possibility that people's blood sample would be provided to Novo Nordisk from their doctors in case of severe allergic reaction that might be caused by OzempicĀ®.
Interventions
Name:
semaglutide
Type:
DRUG
Description:
Patients will be treated with commercially available OzempicĀ® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with OzempicĀ® is independent of the decision to include the patient in the study.
Primary Outcomes
Measure:
Number of adverse events (AEs)
TimeFrame:
From baseline (day 0) to end of study (month 36)
Description:
Count
Trial Information
NCT ID
NCT04469855
Status
Completed
Study Type
OBSERVATIONAL
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025